Immunotherapy approaches for rare pediatric solid tumors: advances and future directions.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pubmed:
25
11
2022
medline:
4
1
2023
entrez:
24
11
2022
Statut:
ppublish
Résumé
Immunotherapy for pediatric tumors is rapidly evolving. From major successes in pediatric hematologic malignancies, immunotherapy utility increased in the pediatric solid tumor landscape. Numerous pediatric solid tumors are defined as rare with limitations in diagnosis and treatment. This review will describe four major immunotherapies used in pediatrics and discuss results seen in rare pediatric tumors. We will also briefly review the challenges of immunotherapy in solid tumors and opportunities to drive this therapy forward. Despite rare success employing immunotherapy for pediatric solid tumors, recently there have been several successes in pediatric rare solid tumors. After describing the evolving landscape of rare pediatric tumors, we will demonstrate the successes or disappointments of immunotherapy. We will describe the mechanism of four immunotherapies used in the pediatrics, followed by the published results. Finally, we will discuss the challenges and opportunities for immunotherapies in pediatric rare tumors. Pediatric rare tumors are lacking in treatment options. Despite numerous disappointments utilizing immunotherapies in the more common pediatric solid tumors, there have been several successes within the pediatric rare tumor landscape. Much work is still needed to enhance our understanding and knowledge on utilizing these immunotherapies for pediatric rare solid tumors.
Identifiants
pubmed: 36420774
doi: 10.1097/MOP.0000000000001206
pii: 00008480-202302000-00013
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-74Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Congress, Orphan Drug Act. 2022, September 29, U.S. Government Publishing Office.
Greenlee RT, Goodman MT, Lynch CF, et al. The occurrence of rare cancers in U.S. adults, 1995–2004. Public Health Rep 2010; 125:28–43.
O’Leary M, Krailo M, Anderson JR, et al. Progress in childhood cancer: 50 years of research collaboration, a report From the Children's Oncology Group. Semin Oncol 2008; 35:484–493.
Ferrari A. The challenge of very rare tumours in childhood: the Italian TREP project. Eur J Cancer 2007; 43:654–659.
U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions (12/14/2018) [press release]. retrieved from https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions
Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21:531–540.
Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000; 24:937–946.
Liu C, Yang N, Zhang D, et al. Clinical cancer immunotherapy: current progress and prospects. Front Immunol 2022; 13:961805.
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117:1137–1146.
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284:1–5.
Gubin MM, Vesely MD. Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res 2022; 28:3917–3928.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–674.
Fridman WH. From cancer immune surveillance to cancer immunoediting: birth of modern immuno-oncology. J Immunol 2018; 201:825–826.
Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 2022; 22:557–575.
Poltavets AS, Vishnyakova PA, Elchaninov AV, et al. Macrophage modification strategies for efficient cell therapy. Cells 2020; 9:1535.
Paijens ST, Vledder A, de Bruyn M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 2021; 18:842–859.
Sun Y, Li F, Sonnemann H, et al. Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer. Cells 2021; 10:2379.
Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: elements and their synergistic function. EBioMedicine 2020; 58:102931.
Xu X, Qiu J, Sun Y. The basics of CAR T design and challenges in immunotherapy of solid tumors – ovarian cancer as a model. Hum Vaccin Immunother 2017; 13:1548–1555.
Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch 2019; 474:449–461.
Gill S, Brudno JN. CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions. Am Soc Clin Oncol Educ Book 2021; (41):e246–e265.
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377:2531–2544.
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378:439–448.
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839–852.
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020; 382:1331–1342.
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021; 384:705–716.
Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398:314–324.
Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci 2019; 15:2548–2560.
Liu Y, Yan X, Zhang F, et al. TCR-T immunotherapy: the challenges and solutions. Front Oncol 2021; 11:794183.
Merchant MS, Cristea MC, Stadtmauer EA, et al. Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma. Cancer Res 2015; 75: (Suppl): 4707–14707.
Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 2016; 22:26–36.
Robbins PF, Morgan AR, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917–924.
Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015; 21:1019–1027.
D’Angelo SP, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov 2018; 8:944–957.
D’Angelo SP, Van Tine BA, Attia S, et al. SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. J Clin Oncol 2021; 39: (Suppl): 11504–111504.
Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46–53.
Faust JR, Hamill D, Kolb EA, et al. An insight into the role of mesothelin in pediatric acute myeloid leukemia. FASEB J 2022; 36 (S1):
Tokatlian T, Asuelime GE, Mock J, et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer 2022; 10:e003826.
Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6:261ra151.
Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 2021; 27:1544–1552.
Hegde M, Joseph SK, Pashankar F, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun 2020; 11:3549.
Gill J, Hingorani P, Roth M, et al. HER2-targeted therapy in osteosarcoma. Adv Exp Med Biol 2020; 1257:55–66.
Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res 2021; 27:1227–1235.
Talbot LJ, Chabot A, Funk A, et al. A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells. Front Immunol 2021; 12:691741.
Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 2019; 25:2560–2574.
Haydar D, Houke H, Chiang J, et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol 2021; 23:999–1011.
Long C, Li G, Zhang C, et al. B7-H3 as a target for CAR-T cell therapy in skull base chordoma. Front Oncol 2021; 11:659662.
Theruvath J, Sotillo E, Mount CW, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med 2020; 26:712–719.
Pinto NR, Albert CM, Taylor M, et al. STRIVE-02: a first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors. J Clin Oncol 2022; 40: (Suppl): 10011–110011.
Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol 2020; 10:1000.
Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022; 603:934–941.
Moghimi B, Muthugounder S, Jambon S, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun 2021; 12:511.
Straathof K, Flutter B, Wallace R, et al. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Sci Transl Med 2020; 12:eabd6169.
Yu L, Huang L, Lin D, et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. J Cancer Res Clin Oncol 2022; 148:2643–2652.
Bhoj VG, Li L, Parvathaneni K, et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol Ther Oncolytics 2021; 20:387–398.
Rosenberg SA, Yanelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159–1166.
Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol 2019; 10:2965.
Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 2020; 13:84.
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642–662.
Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science 2021; 374:1325–1326.
Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol 2020; 6:402–408.
Streby KA, Currier MA, Triplet M, et al. First-in-human intravenous seprehvir in young cancer patients: a phase 1 clinical trial. Mol Ther 2019; 27:1930–1938.
Friedman GK, Johnson JM, Bag AK, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med 2021; 384:1613–1622.
Bernstock JD, Bag AK, Fiveash J, et al. Design and rationale for first-in-human phase 1 immunovirotherapy clinical trial of oncolytic HSV G207 to treat malignant pediatric cerebellar brain tumors. Hum Gene Ther 2020; 31:1132–1139.
Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med 2022; 386:2471–2481.
Schuelke MR, Gundelach JH, Coffey M, et al. Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neurooncol Adv 2022; 4:vdac085.
Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019; 18:155.
Wu Y, Guo Y, Huang A, et al. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med 1997; 185:1327–1335.
Ring EK, Markert JM, Gillespie GY, et al. Checkpoint proteins in pediatric brain and extracranial solid tumors: opportunities for immunotherapy. Clin Cancer Res 2017; 23:342–350.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073–2087. e3.
Llosa NJ, Cruise M, Tamn A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5:43–51.
Chang L, Chang M, Chang HM, et al. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol 2018; 26:e15–e21.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:121–133.
U.S. Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer (10/15/2021) [press release] retrieved from da.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer#:∼:text=FDA%20approves%20atezolizumab%20as%20adjuvant%20treatment%20for%20non-small%20cell%20lung%20cancer,-Share&text=On%20October%2015%2C%202021%2C%20the,Tecentriq%2C%20Genentech%2C%20Inc.)
Naqash AR, Coyne GHO, Moore N, et al. Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS). J Clin Oncol 2021; 39: (Suppl): 11519–111519.
Wedekind MF, Denton NL, Chen C, et al. Pediatric cancer immunotherapy: opportunities and challenges. Pediatric Drugs 2018; 20:395–408.
Davis KL, Fox E, Isikwei E, et al. A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children's Oncology Group Study ADVL1412. Clin Cancer Res 2022; CCR-22-2164. doi: 10.1158/1078-0432.CCR-22-2164. [Online ahead of print].
doi: 10.1158/1078-0432.CCR-22-2164.
Doshi SD, Oza J, Remotti H, et al. Clinical benefit from immune checkpoint blockade in sclerosing epithelioid fibrosarcoma: a translocation-associated sarcoma. JCO Precis Oncol 2021; 5:1–5.
Forrest SJ, Yi J, Kline C, et al. Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers. J Clin Oncol 2021; 39: (Suppl): TS10055.
Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol 2022; Jco2200533doi: 10.1200/JCO.22.00533. [Online ahead of print].
doi: 10.1200/JCO.22.00533.
Pawel BR. SMARCB1-deficient tumors of childhood: a practical guide. Pediatr Dev Pathol 2018; 21:6–28.
Cho BC, Rodriguez Abreu D, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected nonsmall-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 2022; 23:781–792.
Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer 2020; 8:e000957.
Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020; 13:104.
Kim SJ, Khadka D, Seo JH. Interplay between solid tumors and tumor microenvironment. Front Immunol 2022; 13:882718.
Peinado H, Zhang H, Matei IR, et al. Premetastatic niches: organ-specific homes for metastases. Nat Rev Cancer 2017; 17:302–317.
Kaczanowska S, Beury DW, Gopalan V, et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 2021; 184:2033–2052. e21.
Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020; 37:443–455.
Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021; 14:156.
Chen N, Li X, Chintala NK, et al. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol 2018; 51:103–110.
Miao L, Zhang Z, Ren Z, et al. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol 2021; 12:687822.